We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.
The call highlighted the FDA’s new final C. difficile guidance that formalizes a default one‑trial pathway—allowing a single adequate and well‑controlled pivotal trial supported by “confirmatory” evidence (mechanistic/in‑vitro MIC and killing data, molecular mechanism, animal efficacy models, microbiome data, etc.) to meet substantial evidence of effectiveness; Acurx has an FDA meeting planned to align on this, and is initiating an open‑label rCDI pilot of 20 multiply‑recurrent patients (≥3 episodes in the prior 12 months) with a planned interim look at ~10 patients and first patient targeted around August, followed by a planned active‑controlled Phase III and potential LPAD submission for rCDI; the company will use its Phase II data as part of the confirmatory package (Phase II reported ~96% cure rate, 25/25 cured patients free of recurrence at 1 month and 5/5 free at 3 months), will follow the standard 1‑month recurrence endpoint (and extend follow‑up to 8 weeks/56 days to compare to live‑biologic comparators VOWST and REBYOTA), and reinforced program strength with IP (10 patents, including 5 U.S., with one patent extending to December 2039) and recent financing (cash $9.3M as of March 31, ~ $3.1M raised this quarter; 3,389,106 shares outstanding).
Ibezapolstat Phase II showed a ~96% clinical cure rate and 0% recurrence among cured patients at 1 month (25/25 recurrence-free). In a subset, 5/5 patients observed out to 3 months remained recurrence-free, supporting the drug's potential to treat acute CDI and reduce recurrence.
Company launched an exploratory open-label pilot rCDI trial for multiply recurrent C. difficile patients (≥3 episodes in past 12 months), planned as a 20-patient study to inform a potential active-controlled Phase III registration trial in rCDI.
FDA published final guidance indicating one adequate and well-controlled trial plus confirmatory evidence may suffice for C. difficile registration; Acurx plans to meet with FDA and may pursue approval for rCDI under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).
Company secured a new Korea patent covering DNA Pol IIIC inhibitors and an earlier USPTO patent (Feb 2026) extending coverage; total portfolio now includes 10 patents (5 U.S. patents plus patents in Israel, Japan, India, Australia and Korea), with at least one patent extending to December 2039 (subject to extension).
Preclinical data presented at ESCMID show DNA Pol IIIC compounds reduced MRSA tissue burden, achieved potentially therapeutic plasma levels, and preserved gut microbial diversity (distinct from linezolid), supporting broader gram-positive indication potential while sparing the microbiome.
Ibezapolstat has FDA QIDP and Fast Track designations for CDI; in Europe the company has SME status. All preclinical Acurx compounds are eligible for QIDP and Fast Track, which could accelerate development for gram-positive infections.
Cash at quarter end was $9.3M, up from $7.6M at Dec 31, 2025 (+22.4%). The company raised approximately $3.1M gross via its equity line during the quarter and closed a registered direct offering of 825,085 shares at $3.03 plus concurrent short-term warrants (1,650,170 shares exercisable at $2.78, immediately exercised). Registration statement for resale is now effective.
R&D expenses decreased to $0.3M from $0.6M (-50%), G&A decreased to $1.4M from $1.6M (-12.5%), and net loss improved to $1.7M ($0.62 per diluted share) from $2.1M ($2.15 per diluted share) — a ~19% reduction in net loss and a ~71% decrease in loss per diluted share year-over-year.
Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the call over to your host, Mr. Rob Shawah, Chief Financial Officer. Please go ahead, sir.
Thank you, Melissa. Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the first quarter of 2026, which is available on our website at acurxpharma.com. Joining me today is Dave Luci, President and CEO of Acurx, who will start by providing a corporate update and outlook. Following that, I'll provide some highlights of the financial results from the first quarter ended March 31 and then turn the call over to Dave for his closing remarks. As a reminder, during today's call, we'll be making certain forward-looking statements, which are based on current information, assumptions, estimates and projections about future events that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Investors should consider these risks and other information described in our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed yesterday, Monday, May 11, 2026. You are cautioned not to place undue reliance on these forward-looking statements, and Acurx disclaims any obligation to update such statements at any time in the future.
This conference call contains time-sensiti...